Prostate Diseases: Diagnosis and Tests

At Liv Hospital, prostate diseases are diagnosed through advanced imaging, laboratory testing, and expert urological evaluation for accurate and personalized care.

How Are Prostate Diseases Diagnosed at Liv Hospital?

At Liv Hospital, we have moved beyond the era of relying on a single test to diagnose prostate disease. In 2026, we utilize a "Multi-Parametric" approach that integrates biochemical markers, advanced imaging, and digital functional assessments. Because conditions like BPH, prostatitis, and prostate cancer often share clinical features, our goal is to achieve an "Anatomical and Biological Map" of the prostate. This allows our specialists to distinguish between benign growth and aggressive malignancy with unparalleled precision, reducing unnecessary biopsies while ensuring no significant disease is missed.

PSA and Advanced Biomarker Screening

• The Prostate-Specific Antigen (PSA) test remains the frontline tool, but at Liv Hospital, we interpret it with sophisticated nuance.

  • PSA Velocity and Density: We track how quickly your PSA levels change over time and compare the PSA level to the total volume of your prostate (measured via ultrasound).
  • Free/Total PSA Ratio: This helps distinguish between BPH and cancer. A lower ratio often points toward a higher risk of malignancy.
  • Prostate Health Index (phi): For patients in the "gray zone" (PSA between 4 and 10), we use the phi test, a more specific blood marker that significantly improves the accuracy of cancer detection.

Digital Rectal Examination (DRE)

• Despite advancements in technology, the DRE remains a fundamental part of the physical exam. It allows the urologist to manually assess the posterior surface of the prostate gland.

  • Texture and Symmetry: We check for "nodules" (hard lumps), asymmetry, or general tenderness.
  • Clinical Insight: A hard, fixed nodule is a classic sign of potential malignancy, whereas a soft, "boggy" prostate often indicates inflammation or prostatitis. At Liv Hospital, this exam is performed with the utmost discretion and takes only a few seconds.

Uroflowmetry and Post-Void Residual (PVR)

• To diagnose the functional impact of BPH, we perform a Uroflowmetry test.

  • The Process: The patient urinated into a specialized device that measures the speed (flow rate) and volume of the urine.
  • PVR Measurement: Immediately after, a non-invasive bladder scan is performed to see how much urine remains.
  • Obstruction Analysis: A low flow rate combined with a high residual volume confirms that the prostate is physically obstructing the bladder, guiding our treatment decisions for BPH.

Multiparametric MRI (mpMRI): The 2026 Standard

One of the most significant advancements at Liv Hospital is the use of mpMRI before any biopsy is considered.

• Visualizing the Gland: mpMRI provides high-definition images of the prostate’s internal structure, allowing us to see lesions that are invisible to traditional ultrasound.
• PIRADS Scoring: We use the PI-RADS system (1 to 5) to score the likelihood of a suspicious area being a clinically significant cancer. This technology allows us to avoid biopsies in many men with low PI-RADS scores.

MR-TRUS Fusion Biopsy: Precision Targeting

• If an mpMRI identifies a suspicious area, we perform an MR-TRUS Fusion Biopsy.

  • The Technology: We overlay the high-detail MRI images onto a real-time Transrectal Ultrasound (TRUS).
  • Targeted Accuracy: This "GPS-like" guidance allows our surgeons to guide the biopsy needle directly into the suspicious lesion, rather than taking random samples. This results in much higher detection rates for aggressive cancers and fewer "false negative" results.

Transrectal Ultrasound (TRUS) and Volume Calculation

• TRUS is used not just for biopsy guidance but for the accurate measurement of prostate volume.

  • BPH Planning: Knowing the exact size of the prostate is critical for choosing the right surgical path (e.g., Rezum for smaller glands vs. HoLEP for larger ones).
  • PSA Density: We use the volume calculated via TRUS to determine the PSA density, a key metric in our cancer risk assessment protocols at Liv Hospital.

Genetic Testing and Genomic Profiling

• For patients diagnosed with prostate cancer, we go a step further with Genomic Profiling (such as Decipher or Oncotype DX tests).

  • Predictive Biology: These tests analyze the genetic activity within the tumor cells to predict how the cancer is likely to behave.
  • Personalized Management: This helps us decide if a patient can safely stay on "Active Surveillance" or if they require aggressive treatment like robotic surgery or radiation.

UPOINT Classification for Prostatitis

• For patients suffering from the complex symptoms of prostatitis, we use the UPOINT clinical phenotyping system.

  • Urinary symptoms, Psychosocial factors, Organ-specific findings, Infection, Neurological/systemic issues, and Tenderness of muscles.
  • Targeted Therapy: This diagnostic framework ensures that we treat the specific "type" of prostatitis you have, rather than just prescribing generic antibiotics.

Why Liv Hospital for Prostate Diagnosis?

• At Liv Hospital, your diagnostic journey concludes with a "Urology Board Review" for complex cases. Our team of urologists, radiologists, and pathologists meet to discuss your imaging, biopsy results, and functional tests. This ensures that the diagnosis you receive is not just a lab result, but a comprehensive clinical conclusion backed by the highest technology available in 2026. We provide you with a clear, documented path forward, ensuring you have all the information needed to make an empowered decision about your health. At Liv Hospital, we bring clarity to complexity.